Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 8/20 | 0.40 |
| ▸ | PLK1 | P53350 | 4/20 | 0.39 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.37 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.37 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.37 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.37 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.37 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.37 |
| ▸ | FXYD2 | P54710 | 3/20 | 0.37 |
| ▸ | ATP1A4 | Q13733 | 3/20 | 0.37 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ASPH | Q12797 | 1/20 | 0.36 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.36 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6616646 | 1.00 | CXCR2 (0.40) | CXCR2PLK1ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL6617366 | 1.00 | CXCR2 (0.40) | CXCR2PLK1ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL4262382 | 0.82 | ALDH1A1 (0.35) | CXCR2CXCR1LMNA | |
| SCHEMBL7944179 | 0.81 | ABCC8 (0.53) | CXCR2CXCR1LMNA | |
| SCHEMBL7952483 | 0.81 | ABCC8 (0.53) | CXCR2CXCR1LMNA | |
| SCHEMBL7944181 | 0.81 | ABCC8 (0.53) | CXCR2CXCR1LMNA | |
| SCHEMBL6619097 | 0.81 | ALDH1A1 (0.40) | PLK1ATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL6621677 | 0.81 | ALDH1A1 (0.40) | PLK1ATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL6619094 | 0.81 | ALDH1A1 (0.40) | PLK1ATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL24050674 | 0.80 | THRB (0.42) | CXCR2PLK1CXCR1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0877748-B1 | PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE | UNIV LIEGE (BE) | 2004-11-03 | — | — | EP | claimed |
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | claimed |
| US-20030125323-A1 | Use of selective potassium channel openers | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | US | claimed |
| US-20030109519-A1 | Use of selective potassium channel openers | NOVO NORDISK (DK) | 2003-06-12 | — | — | US | claimed |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | NOVO NORDISK A/S (DK) | 2002-03-21 | — | — | US | claimed |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | NOVO NORDISK A/S (DK) | 2002-03-07 | — | — | US | claimed |
| US-5792764-A | ENDOCRINE DISORDERS ESPECIALLY AS A K(ATP)-CHANNEL MODULATOR | NOVO NORDISK A/S (DK) | 1998-08-11 | — | — | US | claimed |
| EP-0877748-B1 | PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE | UNIV LIEGE (BE) | 2004-11-03 | — | — | EP | disclosed |
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | disclosed |
| US-20030125323-A1 | Use of selective potassium channel openers | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | US | disclosed |
| US-20030109519-A1 | Use of selective potassium channel openers | NOVO NORDISK (DK) | 2003-06-12 | — | — | US | disclosed |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | NOVO NORDISK A/S (DK) | 2002-03-21 | — | — | US | disclosed |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | NOVO NORDISK A/S (DK) | 2002-03-07 | — | — | US | disclosed |
| WO-2002000223-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
| US-5792764-A | ENDOCRINE DISORDERS ESPECIALLY AS A K(ATP)-CHANNEL MODULATOR | NOVO NORDISK A/S (DK) | 1998-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125323-A1 | Use of selective potassium channel openers | KCNJ11, KCNJ1, KCNJ2 | CXCR2 4185/4885PLK1 1965/4885ATP1A1 53/4885 |
| US-20030109519-A1 | Use of selective potassium channel openers | KCNJ11, KCNJ2, KCNJ1 | CXCR2 4038/4885PLK1 3791/4885ATP1A1 52/4885 |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | KCNN3, KCNN1, KCNN2 | CXCR2 3575/4885PLK1 595/4885ATP1A1 62/4885 |
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | CD69, IAPP, CD4 | CXCR2 2526/4885PLK1 2762/4885ATP1A1 1552/4885 |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | KCNN3, KCNN2, KCNN1 | CXCR2 3688/4885PLK1 2912/4885ATP1A1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.